Berenberg upgraded Sartorius AG to “buy” from “hold” and raised price target to €250 from €215, calling the ~10% sell‑off overreaction.
Berenberg forecasts 9% bioprocessing division growth and 8% revenue growth in 2026, at the top of Sartorius’s 6‑10% and 5‑9% guidance.
Projected revenue rises to €3.75bn (2026), €4.12bn (2027) and €4.54bn (2028) with adjusted EBITDA margins improving to 31.6% by 2028.
Net debt forecast to fall to €2.77bn by 2028, ROCE rise to 11.1% and free cash flow per share €6.39 in 2028.